• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Solana Company (NASDAQ: HSDT) Strengthens Treasury Strategy with Helius, Anchorage Digital and Twinstake Staking Services

    10/23/25 9:05:00 AM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $HSDT alert in real time by email

    NEWTOWN, Pa., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Solana Company (NASDAQ:HSDT or the "Company") announced that it has entered into agreements with Helius and Twinstake (each, a "Provider," and collectively, the "Providers"), related to non-custodial staking services. The Company is also staking its SOL holdings directly from qualified custody at Anchorage Digital Bank.

    The Providers have developed non-custodial staking and restaking solutions that allow users to delegate, stake, and/or restake their digital assets to earn rewards. Pursuant to the agreements, the Providers will make their platforms available to the Company and provide the Company with certain services, which include staking, voting with staked tokens, and reporting with regard to the staked tokens.

    "This marks an important next step in executing our digital asset treasury strategy," said Joseph Chee, Executive Chairman of HSDT and Chairman of Summer Capital. "By staking with industry leaders like Helius and Twinstake, we are strengthening the operational backbone of our SOL holdings while contributing to the resilience and decentralization of the Solana ecosystem. Both providers rank among the top 25 validators on the Solana network by total SOL staked, signaling their established track record and strong confidence within the community."

    Cosmo Jiang, General Partner at Pantera Capital and Board Observer at HSDT, added: "These partnerships position HSDT to maximize on-chain yield in a secure, compliant and scalable manner. Partnering with top-tier validators trusted by the broader Solana community reinforces our focus on institutional-grade execution and network alignment. As Solana continues to lead in performance and adoption, we see staking as both a core part of our return generation strategy and a reinforcement of our commitment to the network's long-term growth."

    Helius, the leading Solana validator with over 13 million SOL staked, offers institutional-grade staking services and operates SOC 2 Type II-compliant infrastructure, ensuring optimal uptime, performance and security. Twinstake and Anchorage Digital bring complementary strengths in regulated and enterprise-level staking, expanding the Company's exposure to the broader Solana validator ecosystem.

    "Crypto is connecting the internet of value," said Mert Mumtaz, Co-founder and CEO of Helius. "Solana today is the only blockchain network with the scale to onboard all of the world's capital markets, microtransactions, and AI payments. Together with the Solana Company, we're accelerating institutional adoption of Solana, and building the future of the world's trading terminal."

    Solana has historically been the fastest-growing blockchain, leading the industry in transaction revenue, and processing more than 3,500 transactions per second. The network is also the most widely adopted, with an average of around 3.7 million daily active wallets and surpassing 23 billion transactions year-to-date. SOL is financially productive by design, offering a ~7% native staking yield, whereas assets like BTC are non-yield-bearing.

    As an independent treasury company, HSDT's mission is to support the growth and security of tokenized networks by serving as a long-term holder of $SOL, in addition to continuing the development of its neurotech and medical device operations.

    Forward Looking Statements

    This press release contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended. This press release also includes express and implied forward-looking statements regarding the Company's current expectations, estimates, opinions and beliefs that are not historical facts. Such forward-looking statements may be identified by words such as "believes," "expects," "endeavors," "anticipates," "intends," "plans," "estimates," "projects," "should" and "objective" and the negative and variations of such words and similar words. These statements are made on the basis of current knowledge and, by their nature, involve numerous assumptions and uncertainties. Nothing set forth herein should be regarded as a representation, warranty or prediction that we will achieve or are likely to achieve any particular future result. Actual results may differ materially from those indicated in the forward-looking statements because the realization of those results is subject to many risks and uncertainties, including the risk that we may fail to realize the anticipated benefits of the private placement, including the ability of the Company to execute on its digital asset treasury strategy, as well as risks related to economic conditions, fluctuations in the market price of SOL, and the evolving regulatory environment, as well as other factors. Forward-looking statements contained in this press release are made as of the date of this press release, and the Company undertakes no duty to update such information except as required under applicable law.

    About Solana Company

    Solana Company (NASDAQ:HSDT) is a listed digital asset treasury dedicated to acquiring Solana (SOL), created in partnership with Pantera and Summer Capital. Focused on maximizing SOL per share by leveraging capital markets opportunities and onchain activity, Solana Company offers public market investors optimal exposure to Solana's secular growth. https://www.solanacompany.co/



    For additional information, follow us on:

    https://x.com/Solana_Company

    https://www.linkedin.com/company/helius-solana-company/

    Media Contact 
    Helius Medical Technologies, Inc.[email protected]
      
    Pantera Capital Management LP[email protected]
     [email protected]
      
    Summer Capital Limited[email protected]


    Primary Logo

    Get the next $HSDT alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $HSDT

    DatePrice TargetRatingAnalyst
    11/15/2021Outperform → Market Perform
    Noble Capital Markets
    More analyst ratings

    $HSDT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    CORRECTION – Solana Company Announces Updated SOL Holdings and Industry Leading Staking Yield

    NEWTOWN, Pa., Oct. 29, 2025 (GLOBE NEWSWIRE) -- In a release issued under the same headline on Wednesday, October 29th by Solana Company (NASDAQ:HSDT), please note that in the first sentence of the third paragraph, the increase of the amount of "SOL" held should be roughly 0.1 million, not 1 million. The corrected release follows:  Solana Company (NASDAQ:HSDT) (the "Company" or "HSDT") today announced its updated Solana ("SOL") token and cash holdings as of Oct. 29 at 12:00 am ET, as well as its current staking performance. This update reflects the Company's continued execution of its mission to maximize SOL per share through disciplined execution of its digital asset treasury strategy i

    10/29/25 12:20:12 PM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Solana Company Announces Updated SOL Holdings and Industry Leading Staking Yield

    NEWTOWN, Pa., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Solana Company (NASDAQ:HSDT) (the "Company" or "HSDT") today announced its updated Solana ("SOL") token and cash holdings as of Oct. 29 at 12:00 am ET, as well as its current staking performance. This update reflects the Company's continued execution of its mission to maximize SOL per share through disciplined execution of its digital asset treasury strategy including capital deployment, active onchain management, and transparent reporting. As of Oct. 29, the Company and its subsidiaries collectively hold over 2.3 million SOL, which is an increase of roughly 1 million since our last update on Oct. 6. The Company and its subsidiaries also co

    10/29/25 9:00:00 AM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Solana Company (NASDAQ: HSDT) Strengthens Treasury Strategy with Helius, Anchorage Digital and Twinstake Staking Services

    NEWTOWN, Pa., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Solana Company (NASDAQ:HSDT or the "Company") announced that it has entered into agreements with Helius and Twinstake (each, a "Provider," and collectively, the "Providers"), related to non-custodial staking services. The Company is also staking its SOL holdings directly from qualified custody at Anchorage Digital Bank. The Providers have developed non-custodial staking and restaking solutions that allow users to delegate, stake, and/or restake their digital assets to earn rewards. Pursuant to the agreements, the Providers will make their platforms available to the Company and provide the Company with certain services, which include staking,

    10/23/25 9:05:00 AM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $HSDT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Helius Medical Tech downgraded by Noble Capital Markets

    Noble Capital Markets downgraded Helius Medical Tech from Outperform to Market Perform

    11/15/21 10:55:44 AM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Noble Capital Markets initiated coverage on Helius Medical with a new price target

    Noble Capital Markets initiated coverage of Helius Medical with a rating of Outperform and set a new price target of $20.00

    3/24/21 8:02:45 AM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    LADENBURG THALM/SH SH initiated coverage on Helius Medical Technologies

    LADENBURG THALM/SH SH initiated coverage of Helius Medical Technologies with a rating of Buy

    2/12/21 8:21:57 AM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $HSDT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Jiang Cosmo Yi

    3 - Solana Co (0001610853) (Issuer)

    10/31/25 6:51:45 PM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    New insider Chee Choon Wee claimed ownership of 6,830,402 shares (SEC Form 3)

    3 - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Issuer)

    9/25/25 5:00:15 PM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 4 filed by CFO and Treasurer Mathiesen Jeffrey S

    4 - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Issuer)

    7/3/25 8:00:26 PM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $HSDT
    SEC Filings

    View All

    Solana Company filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - Solana Co (0001610853) (Filer)

    10/31/25 9:24:50 AM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Solana Company filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Solana Co (0001610853) (Filer)

    10/29/25 4:05:20 PM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Solana Company filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Solana Co (0001610853) (Filer)

    10/20/25 6:10:22 PM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $HSDT
    Leadership Updates

    Live Leadership Updates

    View All

    Solana Company Executive Chairman's Message: October 20th, 2025

    NEWTOWN, Pa., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Today, Solana Company (NASDAQ:HSDT) released the following letter from the Executive Chairman: We are excited to enter the next phase of our lifecycle with a strong capital base and expanded accessibility for investors. This week will be remembered as a foundational moment for Solana Company (NASDAQ:HSDT). We have made the deliberate choice to move forward with our scheduled registration for resale of the shares purchased by investors in the recent private placement rather than delay it. Whereas some of our peers have decided to postpone it at the first sign of market volatility, we want to explain why we made this decision and why we feel

    10/20/25 10:18:15 AM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Helius Medical Technologies, Inc. Announces Authorized Claim for Payment by Major Healthcare Payer for its Portable Neuromodulation Stimulator (PoNS®) Device

    -Aetna authorizes claim for PoNS Device at out-of-network negotiated price of $18,350, becoming the third payer to join Anthem and United in providing PoNS reimbursement- -Out of Network reimbursement is only the first step towards expanding third-party paid access to PoNS- NEWTOWN, Pa., June 11, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:HSDT) ("Helius" or the "Company"), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced an authorized claim for payment for the PoNS Device from a third major healthcare provider, Aetna Healthcare. "The recent reimbursement approvals from two major

    6/11/25 7:00:00 AM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Helius to Spotlight Study Confirming Improved Long-Term Outcomes from Adherence to PoNS Therapy® at CMSC Annual Meeting

    NEWTOWN, Pa., May 20, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:HSDT), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, announced it will highlight the results of a new study confirming the therapeutic regimen and sustained efficacy of its Portable Neuromodulation Stimulator (PoNS®) device for people with multiple sclerosis (MS) at the 2025 Consortium of Multiple Sclerosis Centers (CMSC) Annual Meeting. The event runs from May 28-31 at the Phoenix Convention Center in Phoenix. Deborah Backus, PT, Ph.D., FACRM – Vice President of Research and Innovation at Atlanta's Shepherd Center, one of six sit

    5/20/25 7:00:00 AM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $HSDT
    Financials

    Live finance-specific insights

    View All

    Helius Medical Technologies, Inc. Provides Updates on Efforts to Achieve Fair Market Access for its Portable Neuromodulation Stimulator (PoNS®) Device

    NEWTOWN, Pa., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:HSDT) ("Helius" or the "Company"), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today provided updates on its efforts to achieve fair market access for its Portable Neuromodulation Stimulator (PoNS) device and announced plans to host a business update call today at 9:00am ET.   "We disagree with the proposed pricing for the PoNS Mouthpiece and are disappointed CMS has once again mapped the Controller pricing to a code for fundamentally different technology," said Dane Andreeff, Helius' President and Chief Executive Officer. "I

    11/18/24 8:01:00 AM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Helius Medical Technologies, Inc. to Release Second Quarter 2024 Financial Results on August 12, 2024

    NEWTOWN, Pa., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:HSDT) ("Helius" or the "Company"), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced that the Company will release its second quarter 2024 financial results on Monday, August 12, 2024, after the market closes. Dane C. Andreeff, President and Chief Executive Officer, and Jeffrey S. Mathiesen, Chief Financial Officer will host a conference call to discuss the results and provide an expanded business update regarding Helius' progress and plans surrounding the U.S. commercialization of PoNS® as follows: Date:Monday, Augus

    8/6/24 4:36:06 PM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Helius Medical Technologies, Inc. to Release First Quarter 2024 Financial Results on May 13, 2024

    NEWTOWN, Pa., May 10, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:HSDT) ("Helius" or the "Company"), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced that the Company will release its first quarter 2024 financial results on Monday, May 13, 2024, after the market closes. Dane C. Andreeff, President and Chief Executive Officer, and Jeffrey S. Mathiesen, Chief Financial Officer will host a conference call to discuss the results and provide an expanded business update regarding Helius' progress and plans surrounding the U.S. commercialization of PoNS® as follows: Date: Monday, May 13, 2

    5/10/24 9:00:00 AM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $HSDT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Helius Medical Technologies Inc.

    SC 13G/A - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Subject)

    11/8/24 5:12:24 PM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G filed by Helius Medical Technologies Inc.

    SC 13G - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Subject)

    5/14/24 4:15:39 PM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G/A filed by Helius Medical Technologies Inc. (Amendment)

    SC 13G/A - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Subject)

    2/13/24 7:09:07 PM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $HSDT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Andreeff Dane bought $8,229 worth of shares (1,284 units at $6.41) (SEC Form 4) (Amendment)

    4/A - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Issuer)

    2/15/24 4:06:00 PM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Andreeff Dane bought $40,475 worth of shares (5,000 units at $8.10) (SEC Form 4)

    4 - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Issuer)

    12/15/23 7:00:42 AM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Andreeff Dane bought $25,675 worth of shares (4,006 units at $6.41) (SEC Form 4)

    4 - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Issuer)

    12/4/23 8:30:12 AM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care